611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
FDA OKs Doptelet for Liver Dz Patients Undergoing ProceduresEven a Mosquito's Spit May Help Make You SickFDA Approves Aimovig to Prevent MigrainesLower Vitamin D levels Linked to More Belly FatCan the Mediterranean Diet Protect Against Smog-Related Deaths?Many Parents Say Restaurant Fare Has Made Kids Sick: PollVarious Clinical Disturbances Precede MS DiagnosisFDA Approves First Drug Aimed at Preventing MigrainesAcute Kidney Injury in Hospital Ups Risk of Later Heart FailurePools, Hot Tubs Can Harbor Dangerous GermsAHA: 'Ideal' Heart Health Eludes More AmericansOrgans From Opioid OD Victims Are Saving Lives: StudyMore Cases in Lettuce-Linked E. Coli Outbreak, But End May Be NearFremanezumab Linked to Fewer Monthly Migraine DaysNew Rabies Test Could Save Lives, Maybe Even Minus the ShotsHealth Tip: Understanding Childhood ArthritisFDA Approves 'Biosimilar' Drug to Treat Certain Types of AnemiaColon Polyp Type May Be Key to Cancer Risk'BioSimilar' Drug Approved to Treat Certain Types of AnemiaHealth Tip: Taming a Pollen AllergyHealth Tip: Identifying Asthma Triggers'Superbug' Surfaces at Poultry Farm in ChinaSun's UV Rays a Threat to Your Eyes, TooMalnutrition Is Associated With Poor Prognosis in Heart FailureAntibiotics Tied to Higher Kidney Stone RiskMore Doubt Cast on Surgery for Spinal Compression FracturesObesity Might Raise Your Risk for A-fibAffected by the EpiPen Shortage? Here's What to DoIs Testing for Zika in U.S. Blood Supply Worth the Cost?FDA Permits Marketing of New Device for Treating GI BleedingPTSD May Raise Odds for Irregular HeartbeatNew Device Cleared for Gastrointestinal BleedingIf Kids Exposed to Pot, Tobacco Smoke, ER Visits RiseEven Mild Concussion Tied to Greater Dementia Risk LaterHealth Tip: Help Prevent E coli InfectionCBD Oil: All the Rage, But Is It Really Safe and Effective?Low Neighborhood Walkability Increases Risk of Asthma in KidsSleep-Deprived Kids at Risk of ObesityStudy IDs Pain Descriptors for Varying Stages of Low Back PainHealth Tip: Prepare for a ColonoscopyFurther Signs That Too Much Sitting Can Raise Clot RiskLightning Can Affect Deep Brain Stimulation DevicesThe Cold Truth About Migraine HeadachesHealth Tip: When To Call Your Doctor If You Have Lower Back PainSkin's 'Good' Bacteria May Be Promising Weapon Against EczemaFirst Death Reported in E. Coli Outbreak Tied to Romaine LettuceVectorborne Diseases Up More Than Two-Fold From 2004 to 2016Health Tip: Recognizing Lung DiseaseBlood Type May Play Role in Death Risk After TraumaU.S. Illnesses Tied to Ticks, Mosquitoes Are Soaring
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine


HealthDay News
Updated: Apr 19th 2018

new article illustration

THURSDAY, April 19, 2018 (HealthDay News) -- For patients with episodic migraine who have failed prior preventive migraine treatments (PMTs), erenumab is associated with an increase in the proportion of patients achieving a ≥50 percent reduction in mean monthly migraine days (MMDs), according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 27 in Los Angeles.

Uwe Reuter, M.D., from The Charité -- University Medicine Berlin, and colleagues conducted a 12-week study in which 246 patients with episodic migraine who had failed two to four prior PMTs were randomly allocated to receive erenumab or placebo. At baseline, 38.6, 37.8, and 22.8 percent of patients had failed two, three, and four prior PMTs, respectively.

The researchers found that the mean MMDs was 9.3 and mean monthly acute migraine-specific medication days (MSMDs) was 4.6. The proportion of patients achieving a ≥50 percent reduction in MMDs was higher in erenumab- versus placebo-treated patients at week 12 (30.3 versus 13.7 percent; odds ratio, 2.73). There were greater reductions in MMDs and MSMDs with erenumab than placebo at week 12 (mean difference in MMDs: −1.61; mean difference in MSMDs: −1.73). Erenumab had a similar safety and tolerability profile to placebo.

"Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief," Reuter said in a statement.

The study was funded by Novartis, the manufacturer of erenumab.

Press Release
More Information